Abstract
More people are diagnosed with thyroid cancer than any other endocrine tumor. Differentiated thyroid cancer is often treated by removing the thyroid gland (thyroidectomy), iodizing radiation, or inhibiting thyroid stimulating hormone (TSH). Advanced thyroid carcinomas are notoriously resistant to chemotherapy, thus the pursuit of alternative treatments is vital. The best methods for treating individuals with advanced nonmedullary and medullary thyroid carcinomas are discussed in this post. Numerous tyrosine kinase inhibitors and antiangiogenic inhibitors, two types of novel target therapy, have shown promise in studies for individuals with thyroid cancer. Both the positive and unfavourable outcomes of clinical studies of these drugs were addressed. The findings presented here are encouraging, but more study is required to establish whether or not this method is effective in the treatment of thyroid cancer.
Graphical Abstract
[1]
Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide.GLOBOCAN 2002 IARC Cancer- Base No5, version 20 2004.
[2]
Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five
Continents, vol IX. IARC Press, International Agency for Research
on Cancer; 2007.
[3]
Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control 2009; 20(1): 75-86.
[4]
Ozgun A, Tuncel T, Emirzeoglu L, et al. Malignant melanoma and papillary thyroid carcinoma that were diagnosed concurrently and treated simultaneously: A case report. Oncol Lett 2015; 9(1): 468-70.
[5]
Liska J, Altanerova V, Galbavy S, Stvrtina S, Brtko J. Thyroid tumors: histological classification and genetic factors involved in the development of thyroid cancer. Endocr Regul 2005; 39(3): 73-83.
[6]
Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 1998; 9(7): 695-701.
[7]
Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000; 11(9): 1083-9.
[8]
Matsuo K, Tang SH, Zeki K, et al. Aberrant DNA methylation in human thyroid tumors. J Clin Endocrinol Metab 1993; 77: 991-5.
[9]
Matsuo K, Tang SH, Fagin JA. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Mol Endocrinol 1991; 5(12): 1873-9.
[11]
Gire V, Wynford-Thomas D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 2000; 19(6): 737-44.
[12]
Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989; 4(2): 159-64.
[13]
Suarez HG, Du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990; 5(4): 565-70.
[14]
Shi YF, Zou MJ, Schmidt H, et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991; 51(10): 2690-3.
[15]
Amendoeira I, Maia T, Sobrinho-Simões M. 2018 Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): impact on the reclassification of thyroid nodules. Endocr Relat Cancer 2018; 25: R247-58.
[16]
Na HY, Park SY. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: its updated diagnostic criteria, preoperative cytologic diagnoses and impact on the risk of malignancy. J Pathol Transl Med 2022; 56(6): 319-25.
[17]
Bychkov A, Jung CK, Liu Z, Kakudo K. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice: perspectives for surgical pathology and cytopathology. Endocr Pathol 2018; 29: 276-88.
[18]
Can N, Celik M, Sezer YA, et al. Follicular morphological characteristics may be associated with invasion in follicular thyroid neoplasms with papillary-like nuclear features. Bosn J Basic Med Sci 2017; 17: 211-20.
[19]
Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 1995; 133(5): 513-22.
[20]
Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60(4): 557-63.
[21]
Castellone MD, Santoro M. Dysregulated RET signaling in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37(2): 363-74.
[22]
Fusco A, Grieco M, Santoro M. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987; 328(6126): 170-2.
[23]
Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto’s thyroiditis. Laryngoscope 1997; 107(1): 95-100.
[24]
Grieco M, Cerrato A, Santoro M, Fusco A, Melillo RM, Vecchio G. Cloning and characterization of H4(D10S170), a gene involved in RET rearrangements in vivo. Oncogene 1994; 9(9): 2531-5.
[25]
Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci USA 1992; 89(5): 1616-20.
[26]
Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; A novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994; 9(2): 509-16.
[27]
Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997; 57(9): 1690-4.
[28]
Caudill CM, Zhu Z, Ciampi R, Stringer JR, Nikiforov YE. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab 2005; 90(4): 2364-9.
[29]
Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab 2001; 86(7): 3211-6.
[30]
Bongarzone I, Pierotti MA, Monzini N, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989; 4(12): 1457-62.
[31]
Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997; 15(11): 1263-73.
[32]
Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89(5): 1517-22.
[33]
Viglietto G, Chiappetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995; 11(6): 1207-10.
[34]
Zou M, Shi Y, Farid NR, et al. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 1994; 73: 176-1780.
[35]
Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998; 4(2): 287-94.
[36]
Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001; 86(8): 3746-53.
[37]
De Maria R, Elisei R, Giuffrida D, Machens A. Thyroid cancer guidelines 2011. Available from: http://www.startoncology. net/site/
[38]
Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28(7): 742-62.
[40]
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16(2): 109-42.
[41]
Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 2008; 37: 481-96.
[42]
Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 2005; 200: 378-92.
[43]
Cohen EEW, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008; 26(15): 6025.
[44]
Goulart B, Carr L, Martins R G, et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol 2008; 26(15): 6062.
[45]
Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16(21): 5260-8.
[46]
Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[ 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91(2): 498-505.
[47]
Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26(29): 4714-9.
[48]
Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27(10): 1675-84.
[49]
Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011; 165(2): 315-22.
[50]
Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010; 28(14): 2323-30.
[51]
Cabanillas M E, Kurzrock R, Sherman S I, et al. Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) J Clin Oncol 2010; 28(15): 5586.
[52]
Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28(5): 767-72.
[53]
Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95(6): 2664-71.
[54]
Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30: 134-41.
[55]
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39(1): 1-10.
[56]
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541(7637): 321-30.
[57]
Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 2016; 47(1): 52-63.
[58]
Okubo Y, Yamamoto Y, Sato S, et al. Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution. Virchows Arch 2022; 480(5): 979-87.
[59]
Rudolph N, Dominguez C, Beaulieu A, et al. The morbidity of reoperative surgery for recurrent benign nodular goitre: impact of previous unilateral thyroid lobectomy versus subtotal thyroidectomy. J Thyroid Res 2014; 2014: 231857.
[60]
Leiker AJ, Yen TW, Cheung K, et al. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of “suspicious for papillary thyroid cancer.”. Surgery 2013; 154: 1307-13.
[61]
Khavanin N, Mlodinow A, Kim JYS, et al. Predictors of 30-day readmission after outpatient thyroidectomy: an analysis of the 2011 NSQIP data set. Am J Otolaryngol 2014; 35: 332-9.
[62]
Terris DJ, Snyder S, Carneiro-Pla D, et al. American Thyroid Association statement on outpatient thyroidectomy. Thyroid 2013; 23: 1193-202.
[63]
Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg 2013; 150: 249-56.
[64]
Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27(23): 3794-801.
[65]
Santarpia L, Ye L, Gagel RF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 2009; 266(1): 99-113.
[66]
Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23(24): 5474-83.
[67]
Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26(29): 4708-13.
[68]
Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29(19): 2660-6.
[69]
Bible KC, Smallridge RC, Maples WJ, et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers Proceedings of the American Society of Clinical Oncology vol. 272009
[70]
Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008; 14(17): 5459-65.
